Unique ID issued by UMIN | UMIN000005270 |
---|---|
Receipt number | R000006268 |
Scientific Title | Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system. |
Date of disclosure of the study information | 2011/04/01 |
Last modified on | 2018/01/02 21:37:53 |
Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system.
Determination of optimal 5ASA dose for keeping remission of UC patients by FICE colonoscopy
Evaluation of optimal 5ASA dose in order to determine for keeping remission of patients with ulcerative colitis by colonoscopy using FICE (flexible spectral imaging color enhancement) system.
Determination of optimal 5ASA dose for keeping remission of UC patients by FICE colonoscopy
Japan |
Ulcerative colitis
Medicine in general | Gastroenterology |
Others
NO
To determine the optical 5ASA dose to keep remission in patients with ulceraitive colitis by FICE magnifing colonoscopy
Safety,Efficacy
non-relapse rate by CAI score after one year
clinical Activity Index (CAI)
vascular grading (VG)
vascular score (VS)
non-relapse rate after 3,6,9 months
inflammatory response score(WBC, Plt, ESR, CRP)
pathological Matts gradings
safety
remission period (month)
Interventional
Parallel
Randomized
Open -no one is blinded
Dose comparison
6
Treatment
Medicine | Device,equipment |
GroupA:Pentasa4g/day or Asacol 3.6g/day (VS>5),same dose
GroupB:Pentasa4g/day or Asacol 3.6g/day (VS=5),same dose
GroupC:Pentasa4g/day or Asacol 3.6g/day (VS=5), decrease dose to Pentasa3g/day or Asacol 2.4g/day
GroupD:Pentasa2-3g/day or Asacol 2.4g/day (VS>5), same dose
GroupE:Pentasa2-3g/day or Asacol 2.4g/day (VS>5), increase dose to Pentasa4g/day or Asacol 3.6g/day
GroupF:Pentasa2-3g/day or Asacol 2.4g/day (VS=5),same dose
Not applicable |
Not applicable |
Male and Female
Patients with quiescent ulcerative colitis who can accept colonoscopy
Patients whose CAI is 3 or less
Patients who takes mesalazine
Patients who cannot accept colonoscopy
Patients who have no agreement of this study
Patients who is pregnant or possibly be pregnant
Patients who had operation of total or partial colectomy
Patients who got to start to take treamtents such as;
-sterids (intravenous, peroral, enema and suppo) within 4 weeks
-metrinidazole within 4 weeks
-infliximab within 4 weeks
-elemental diet or IVH within 4 weeks
-cyclosporine or tacrolimus within 4 weeks
-azathiopurine or 6MP within 4 weeks
-mesalazine enema or suppo within 4 weeks
-increase or decrease the mesalazine dose within 4 weeks
180
1st name | |
Middle name | |
Last name | Shingo kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
1981 kamoda, Kawagoe City, Saitama, Japan
049-228-3564
skato@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Shingo kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
1981 kamoda, Kawagoe City, Saitama, Japan
+81-49-228-3564
skato@saitama-med.ac.jp
Saitama Medical Center, Saitama Medical University
Saitama Medical Center, Saitama Medical University
Other
NO
2011 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2011 | Year | 04 | Month | 01 | Day |
2011 | Year | 04 | Month | 01 | Day |
2017 | Year | 03 | Month | 31 | Day |
2011 | Year | 03 | Month | 17 | Day |
2018 | Year | 01 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006268